Fortress Biotech Inc is a biopharmaceutical company focused on developing and commercializing innovative therapies and technologies to address unmet medical needs
The company collaborates with various partners to identify and advance novel drug candidates across multiple therapeutic areas, including oncology, dermatology, and rare diseases. By leveraging its diverse portfolio of subsidiaries and strategic collaborations, Fortress aims to bring new treatments to the market and improve patient outcomes. Their approach combines cutting-edge research with robust clinical development strategies to enhance the effectiveness and accessibility of their therapies.
Fortress Biotech shares are trading lower by 20% Friday afternoon. The company announced the pricing of a $8 million registered direct offering and concurrent private placements.
The CNN Money Fear and Greed index showed some decline in overall market sentiment, but the index remained in the "Extreme Greed" zone on Friday. U.S. stocks closed slightly lower on Friday, but the S&P 500 closed out last year with a gain of 24.2%. The index gained for nine consecutive weeks, notching its best winning streak since 2004.
U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling more than 50 points on Friday. The Dow traded down 0.17% to 37,644.68 while the NASDAQ fell 0.48% to 15,022.70. The S&P 500 also fell, dropping, 0.33% to 4,767.78.
U.S. stocks turned lower midway through trading, with the Nasdaq Composite falling more than 100 points on Friday. The Dow traded down 0.34% to 37,583.72 while the NASDAQ fell 0.73% to 14,984.98. The S&P 500 also fell, dropping, 0.47% to 4,760.73.
Shares of Lantheus Holdings, Inc. (NASDAQLNTH) fell sharply during Monday’s session after the company and POINT Biopharma announced topline results from the pivotal phase 3 SPLASH study in metastatic castration-resistant prostate cancer.
